Summit Therapeutics is trying to turn one experimental cancer drug into a much bigger business by testing it across many major tumor types and partnering with well-known groups to broaden where it can be used. The big question is whether the results and regulators line up in time, since the company has no product sales today and is betting heavily on this single program.Read more
Summit Therapeutics is betting big on a single cancer drug that’s being tested across many types of tumors, which could open a path to much broader use if the results hold up. The upside comes with a clear catch: the company still needs key regulators to sign off, and any trial disappointment could quickly change the story.Read more
Catalysts About Summit Therapeutics Summit Therapeutics is a biopharmaceutical company focused on developing and commercializing ivonescimab for cancer patients across multiple solid tumor indications. What are the underlying business or industry changes driving this perspective?Read more
No trending discussion available.
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.
